Drugs / JS105
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06208410 | Jan 2024 → Feb 2027 expected | neoplasm | Risen (Suzhou) Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07207070 | Nov 2025 → May 2029 expected | breast cancer | Risen (Suzhou) Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JS105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06208410 ↗ |
| Route | Oral | “JS105 is administered once daily, orally” NCT06208410 ↗ |